IL-6 Antikörper

Produktnummer ABIN1383944

Produktdetails anti-IL-6 Antikörper

Target: IL-6 (IL6) (Interleukin 6 (IL6))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser IL-6 Antikörper ist unkonjugiert

Applikation: ELISA, Flow Cytometry (FACS), Functional Studies (Func), ELISpot

Spezifität: Recognises both natural and recombinant human IL-6

Aufreinigung: Ion exchange chromatography

Sterilität: 0.22 μm filtered

Immunogen: Recombinant human IL-6,Myeloma X63/AG.8653 x Balb/c spleen cells

Klon: B-E8

Isotyp: IgG1 kappa

Biological Activity Comment: Inhibits IL-6 induced proliferation on XG1 Cell line

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Phosphate-buffered saline. Sterile-filtered through 0.22 μm. Carrier and preservative free

Konservierungsmittel: Without preservative

Lagerung: 4 °C

Informationen zur Lagerung: Stable at +2-8°C for 12 months. For longer storage freeze aliquots.

Referenzen für anti-IL-6 Antikörper (ABIN1383944)

Sprynski, Hose, Caillot, Réme, Shaughnessy, Barlogie, Seckinger, Moreaux, Hundemer, Jourdan, Meissner, Jauch, Mahtouk, Kassambara, Bertsch, Rossi, Goldschmidt, Klein: "The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor." in: Blood, Vol. 113, Issue 19, pp. 4614-26, (2009) (PubMed).

Adam, Rabe, Suthaus, Grötzinger, Rose-John, Scheller: "Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor." in: Journal of virology, Vol. 83, Issue 10, pp. 5117-26, (2009) (PubMed).

Moreau, Garban, Attal, Michallet, Marit, Hulin, Benboubker, Doyen, Mohty, Yakoub-Agha, Leyvraz, Casassus, Avet-Loiseau, Garderet, Mathiot, Harousseau: "Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma." in: Blood, Vol. 112, Issue 9, pp. 3914-5, (2008) (PubMed).

Garban, Attal, Michallet, Hulin, Bourhis, Yakoub-Agha, Lamy, Marit, Maloisel, Berthou, Dib, Caillot, Deprijck, Ketterer, Harousseau, Sotto, Moreau: "Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma." in: Blood, Vol. 107, Issue 9, pp. 3474-80, (2006) (PubMed).

Moreau, Hullin, Garban, Yakoub-Agha, Benboubker, Attal, Marit, Fuzibet, Doyen, Voillat, Berthou, Ketterer, Casassus, Monconduit, Michallet, Najman, Sotto, Bataille, Harousseau: "Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol." in: Blood, Vol. 107, Issue 1, pp. 397-403, (2005) (PubMed).

Song, Torphy, Griswold, Shealy: "Coming of age: anti-cytokine therapies." in: Molecular interventions, Vol. 2, Issue 1, pp. 36-46, (2004) (PubMed).

Moreaux, Legouffe, Jourdan, Quittet, Rème, Lugagne, Moine, Rossi, Klein, Tarte: "BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone." in: Blood, Vol. 103, Issue 8, pp. 3148-57, (2004) (PubMed).

Derhaschnig, Bergmair, Marsik, Schlifke, Wijdenes, Jilma: "Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia." in: Critical care medicine, Vol. 32, Issue 5, pp. 1136-40, (2004) (PubMed).

Smith, Barg, Weedon, Papengelis, Smeets, Tak, Kraan, Coleman, Ahern: "Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints." in: Annals of the rheumatic diseases, Vol. 62, Issue 4, pp. 303-7, (2003) (PubMed).

Ancey, Menet, Corbi, Fredj, Garcia, Rücker-Martin, Bescond, Morel, Wijdenes, Lecron, Potreau: "Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation." in: Cardiovascular research, Vol. 59, Issue 1, pp. 78-85, (2003) (PubMed).

Choy: "Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis." in: Annals of the rheumatic diseases, Vol. 62 Suppl 2, pp. ii68-9, (2003) (PubMed).

Derenne, Monia, Dean, Taylor, Rapp, Harousseau, Bataille, Amiot: "Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells." in: Blood, Vol. 100, Issue 1, pp. 194-9, (2002) (PubMed).

Delneste, Charbonnier, Herbault, Magistrelli, Caron, Bonnefoy, Jeannin: "Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages." in: Blood, Vol. 101, Issue 1, pp. 143-50, (2002) (PubMed).

Leblond, Dhedin, Mamzer Bruneel, Choquet, Hermine, Porcher, Nguyen Quoc, Davi, Charlotte, Dorent, Barrou, Vernant, Raphael, Levy: "Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 19, Issue 3, pp. 772-8, (2001) (PubMed).

Jego, Bataille, Pellat-Deceunynck: "Interleukin-6 is a growth factor for nonmalignant human plasmablasts." in: Blood, Vol. 97, Issue 6, pp. 1817-22, (2001) (PubMed).

Menetrier-Caux, Thomachot, Alberti, Montmain, Blay: "IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells." in: Cancer research, Vol. 61, Issue 7, pp. 3096-104, (2001) (PubMed).

Corbellino, Bestetti, Scalamogna, Calattini, Galazzi, Meroni, Manganaro, Fasan, Moroni, Galli, Parravicini: "Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy." in: Blood, Vol. 98, Issue 12, pp. 3473-5, (2001) (PubMed).

Haddad, Paczesny, Leblond, Seigneurin, Stern, Achkar, Bauwens, Delwail, Debray, Duvoux, Hubert, Hurault de Ligny, Wijdenes, Durandy, Fischer: "Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial." in: Blood, Vol. 97, Issue 6, pp. 1590-7, (2001) (PubMed).

Kube, Holtick, Vockerodt, Ahmadi, Haier, Behrmann, Heinrich, Diehl, Tesch: "STAT3 is constitutively activated in Hodgkin cell lines." in: Blood, Vol. 98, Issue 3, pp. 762-70, (2001) (PubMed).

Foussat, Wijdenes, Bouchet, Gaidano, Neipel, Balabanian, Galanaud, Couderc, Emilie: "Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes." in: European cytokine network, Vol. 10, Issue 4, pp. 501-8, (2000) (PubMed).

Details zu IL-6

Target: IL-6 (IL6) (Interleukin 6 (IL6))

Andere Bezeichnung: IL-6 (IL6 Produkte)

Synonyme: BSF2 antikoerper, HGF antikoerper, HSF antikoerper, IFNB2 antikoerper, IL-6 antikoerper, Il-6 antikoerper, ILg6 antikoerper, Ifnb2 antikoerper, il6 antikoerper, CHIL-6 antikoerper, interleukin 6 antikoerper, interleukin-6 antikoerper, IL6 antikoerper, Il6 antikoerper, il-6 antikoerper, IL-6 antikoerper

Pathways: TLR Signalweg, Hormone Transport, Negative Regulation of Hormone Secretion, Myometrial Relaxation and Contraction, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Regulation of Carbohydrate Metabolic Process, Autophagie, Cell RedoxHomeostasis, Cancer Immune Checkpoints, Inflammasome